Dr. Olivier Danos is the Chief Scientific Officer for REGENXBIO. Prior to joining REGENXBIO, Dr. Danos was Senior Vice President, Cell and Gene Therapy at Biogen Inc. At Biogen, Dr. Danos led company efforts dedicated to identifying and developing new technologies for gene transfer and genome engineering. Dr. Danos also co-founded Lysogene, a NAV Technology Licensee focused on the development of gene therapy product candidates for the treatment of Mucopolysaccharidosis Type IIIA.
Prior to Biogen, Dr. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Earlier in his career, Dr. Danos was Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon and Senior Director of Research at Somatix Therapy Corporation. Dr. Danos has directed research focused on gene therapy at the Necker – Enfants Malades Hospital in Paris, the French National Centre for Scientific Research and the Pasteur Institute in Paris.